- uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
- uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
- uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
- uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.77 |
---|---|
High | 4.78 |
Low | 4.48 |
Bid | 4.40 |
Offer | 4.68 |
Previous close | 4.75 |
Average volume | 612.45k |
---|---|
Shares outstanding | 47.84m |
Free float | 43.11m |
P/E (TTM) | -- |
Market cap | 227.23m USD |
EPS (TTM) | -6.47 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 21:00 BST.
More ▼